C. Yun
Materials Chemistry · Nature · 2007–2016
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Materials Chemistry — 5 citations into it
Whom C. Yun trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Randy J. Read
- G. Murshudov
- Xuewu Zhang
- A. W. Schüttelkopf
- J. Stamos
- A. Vagin
- H. Greulich
- M. Sliwkowski
- D. V. van Aalten
- E. Dodson
Who trusts C. Yun overall
Papers from C. Yun's perspective
Ordered by how strongly the researchers C. Yun trusts endorse each paper. Same corpus, a different order for every researcher.
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
- Improved methods for building protein models in electron density maps and the location of errors in these models.
- Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
- Refinement of macromolecular structures by the maximum-likelihood method.
- Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (Journal of Biological Chemistry)
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers (International Journal of Cancer)
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (PLoS Medicine)
- ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. (Cancer Research)
- ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors (Nature Reviews. Cancer)
Their papers
- Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. (2007) — 1,098 citations
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (2008) — 2,013 citations
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (2009) — 979 citations
- Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors (2016) — 757 citations